Yahoo! Finance Canada report covering Black Titan Corporation (BTTC) market action, institutional positioning, and fundamental catalysts.
Why BTTC Stock dropped -8.05% Today — RQD Quant Desk Flash
Black Titan Corporation (BTTC) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is BTTC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Black Titan Corporation (NASDAQ: BTTC) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $0.32 (-8.05% 1D, market cap $5.3M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, BTTC ranks #596 in composite RQD confidence.
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does BTTC compare to CELZ and LIMN in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), BTTC carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CELZ (Creative Medical Technology Holdings Inc.) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $5.2M) and LIMN (Liminatus Pharma Inc. (Class A)) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $3.9M). Among the 5-stock peer group, BTTC leads on earnings multiple (N/A) while PMCB leads on capital efficiency (-30.2% ROIC).
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for BTTC?
▼
Per BTTC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-07-31, CIK 0002034400), Black Titan Corporation generated $0 in revenue, -$163.2K in net income, and -$143.2K in free cash flow against $0 in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
⚔️ Adversarial Opposing Case: What Could Spark a BTTC Turnaround Squeeze
While BTTC currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.45) and Max Pain ($0.34) forces dealer call-delta covering toward $10.55.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Why BTTC Stock dropped -8.05% Today — RQD Quant Desk Flash
Black Titan Corporation (BTTC) dropped -8.05% to $0.32, trading at 2% of its 52-week range ($0.32 – $10.05). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($0.32 – $10.05) with RSI-14 at 41.2 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.32 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Yahoo! Finance Canada report covering Black Titan Corporation (BTTC) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Black Titan Corporation (BTTC) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Black Titan Corporation (BTTC) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Black Titan Corporation (BTTC) market action, institutional positioning, and fundamental catalysts.
Company Also Announces $7 Million Strategic Investment and Associated Leadership TransitionSUMMIT, N.J., April 28, 2026 (GLOBE NEWSWIRE) -- Aterian, Inc. (Nasdaq: ATER) (“Aterian” or the “Company”), a consumer products c
NEW YORK, NY / ACCESS Newswire / January 23, 2026 / As the "DeFi-as-a-Service" (DaaS) narrative matures, public equity markets are witnessing a new phenomenon: the "Infrastructure Pivot." This week's primary focus is Bla
NEW YORK CITY, NEW YORK / ACCESS Newswire / January 20, 2026 / The very concept of an "investment" is being redefined. High barriers to entry are being dismantled by technology, creating a more democratized landscape. Th
NEW YORK, NY / ACCESS Newswire / January 20, 2026 / A generation is coming of age with no memory of, or patience for, traditional banking. Their expectation is a financial world that lives on a mobile device - instant, i
NEW YORK, NY / ACCESS Newswire / January 16, 2026 / Black Titan Corporation (NASDAQ:BTTC) (the "Company" or "Black Titan") today announced that it has entered into a securities purchase agreement with a U.S.-based instit
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BTTC)
- ✓Walkthrough of BTTC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
BTTC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on BTTC today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for BTTC. Explore sector supply chains on /butterfly.
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BTTC)
1. Head-to-Head Health Care Peer Comparison (BTTC vs. CELZ, LIMN, CRIS, PMCB)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Black Titan Corporation (BTTC) ranks #596 by composite RQD confidence (38/100, grade D-) and #942 by equity capitalization ($5.3M). Within this direct 5-issuer industry benchmark cohort, BTTC leads on earnings valuation at N/A trailing P/E, while PMCB leads on capital efficiency and profitability with -30.2% ROIC and — gross margin. BTTC currently leads its immediate peer cohort in composite quantitative strength at 38/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BTTC
ACTIVE
Black Titan Corporation | D- | 38/100 | — | — | — | -8.05% | $5.3M | Benchmark Subject |
| CELZ Creative Medical Technology Holdings Inc. | E | 20/100 | — | 63.4% | -35.0% | -3.45% | $5.2M | /celz-vs-bttc → |
| LIMN Liminatus Pharma Inc. (Class A) | E | 34/100 | — | — | -35.0% | -2.59% | $3.9M | /limn-vs-bttc → |
| CRIS Curis Inc. | E | 27/100 | — | — | -35.0% | +9.39% | $3.7M | /cris-vs-bttc → |
| PMCB PharmaCyte Biotech Inc. | D- | 35/100 | — | — | -30.2% | -9.03% | $3.6M | /pmcb-vs-bttc → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)
SEC EDGAR 10-K • FILED 2025-07-31 • CIK 0002034400In its most recent audited fiscal period (FY2025, filed 2025-07-31), Black Titan Corporation (BTTC) reported GAAP revenue of $0 , GAAP net income of -$163.2K, operating cash flow of -$143.2K, and free cash flow of -$143.2K . On the balance sheet, BTTC closed FY2025 with $0 in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-07-31 | $0 | -$163.2K | -$143.2K | -$143.2K | — | — |
3. BTTC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs BTTC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Black Titan Corporation (NASDAQ: BTTC) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $0.32 (-8.05% 1D, market cap $5.3M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, BTTC ranks #596 in composite RQD confidence.
How does BTTC compare to CELZ and LIMN in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), BTTC carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CELZ (Creative Medical Technology Holdings Inc.) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $5.2M) and LIMN (Liminatus Pharma Inc. (Class A)) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $3.9M). Among the 5-stock peer group, BTTC leads on earnings multiple (N/A) while PMCB leads on capital efficiency (-30.2% ROIC).
What are the biggest fundamental strengths and SEC risk factors for BTTC?
Per BTTC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-07-31, CIK 0002034400), Black Titan Corporation generated $0 in revenue, -$163.2K in net income, and -$143.2K in free cash flow against $0 in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is BTTC trading relative to its 50-day, 200-day, and 52-week technical levels?
BTTC last traded at $0.32 (-8.05% on volume of 208,378 shares), positioning the stock -28.89% below its 50-day simple moving average ($0.45) and -68.93% below its 200-day simple moving average ($1.03). Across its 52-week range of $0.32 to $10.05, BTTC sits at the 0.0% percentile with a 14-day RSI of 41.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.36).
BTTC Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is BTTC stock moving today?
Why BTTC Stock dropped -8.05% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
BTTC — Black Titan Corporation: What the Facts Mean to a Prospective Investor
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, BTTC scores 38 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars break down as follows:
- Fundamental Cash Engine: 10 / 20. The rating cites ROIC of 0% and an FCF yield of -2.73%. For a prospective investor, this means the business is not currently generating returns on invested capital or positive free cash flow, so the stock's value rests on future earnings that the source data does not evidence.
- Whale 13F Flow: 6 / 20. The rating reflects institutional accumulation and options positioning. Because the holders section is empty in the source data, the specific institutional signal behind this score cannot be independently verified here.
- Insider Conviction: 5 / 20. The rating reflects SEC Form 4 and Congressional PTR cluster flow. Insider flow is weighted lightly, and the detailed trades are not itemized in the source data.
- Macro Regime Fit: 7 / 20. The rating cites a beta of 1.0 and sector sensitivity. A beta of 1.0 indicates market-level volatility relative to the broader market, but the score suggests limited alignment with the current macro regime.
- Forensic Balance Sheet: 10 / 20. The rating cites an Altman Z of 2.5, a Piotroski F of 1/9, and Debt/Equity of 0.5. The Piotroski reading of 1/9 is a notable weakness in financial-health screening, while the Altman and leverage figures are moderate.
Taken together, the score points to a stock where upside depends on a turnaround in cash generation that is not yet visible in the reported figures. The sub-$1 price, a 52-week range of $0.32 to $10.05, and a $5.3M market capitalization describe a highly speculative and illiquid-profile equity. Prospective investors should treat the rating as a warning on balance-sheet and cash-flow quality rather than as a valuation signal.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 (filed 2025-07-31) | $0.0M | $0.0M | $-0.2M | N/A | $-0.1M | N/A | N/A |
Per the SEC financials, FY 2025 reported zero revenue and zero operating income, a net loss of $-0.2M, and free cash flow of $-0.1M. Gross, operating, and net margins are each recorded as 0% in the market data, and ROIC is 0%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 1/9, and Debt/Equity is 0.5. The reported cash and debt balances are not available in source data, so the balance-sheet posture can only be characterized through the rating's forensic pillar.
Recent Catalysts & News Wire Analysis
The news wire contains five items, all tagged with BTTC as the related symbol. Four are Market Wire items flagged YELLOW, consisting of Yahoo! Finance Canada seasonal-chart and quote pages whose headlines reference other companies (Phunware, Youxin Technology, Ahasolar Technologies, AXIL Brands). Their summaries are generic and contain no company-specific operating news. One item is a CATALYST flagged GREEN, headlined as Arena Group Holdings (AREN) rising 19% to $1.12 toward a $1.18 resistance level; its summary field references an unrelated domain and it does not describe a BTTC event. The risk watch item is that none of the wire items provide a verifiable BTTC-specific fundamental catalyst. The Butterfly Supply-Chain Graph reports no supply-chain relationships and no proprietary signals.
Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples
The Butterfly Supply-Chain Graph lists the supply chain as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies are therefore not available in source data. Sector correlation and second-order bottlenecks cannot be mapped from the provided materials. A prospective investor should note that the absence of mapped links means ripple effects from suppliers, customers, or peer companies cannot be assessed here.
Open Questions
- What is the company's actual product pipeline and revenue model, given that the source data reports zero revenue in FY 2025?
- What are the reported cash and debt balances, which are listed as N/A in the financials?
- Why are FY 2025 net losses reported without a corresponding EPS figure, and what is the share count?
- What drove the stock's 52-week decline from $10.05 to $0.32, and is there a listing-compliance or going-concern issue behind it?
- Which institutional holders and insiders are behind the whale and insider pillar scores, since the holders section is empty?
BTTC Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Black Titan Corporation (BTTC) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering Black Titan Corporation (BTTC) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Black Titan Corporation (BTTC) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Black Titan Corporation (BTTC) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Black Titan Corporation (BTTC) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Black Titan Corporation (BTTC) market action, institutional positioning, and fundamental catalysts.
Company Also Announces $7 Million Strategic Investment and Associated Leadership TransitionSUMMIT, N.J., April 28, 2026 (GLOBE NEWSWIRE) -- Aterian, Inc. (Nasdaq: ATER) (“Aterian” or the “Company”), a consumer products c
NEW YORK, NY / ACCESS Newswire / January 23, 2026 / As the "DeFi-as-a-Service" (DaaS) narrative matures, public equity markets are witnessing a new phenomenon: the "Infrastructure Pivot." This week's primary focus is Bla
NEW YORK CITY, NEW YORK / ACCESS Newswire / January 20, 2026 / The very concept of an "investment" is being redefined. High barriers to entry are being dismantled by technology, creating a more democratized landscape. Th
BTTC Bull vs. Bear Conversation Board — What's Your Call at $0.32?
🔥 Official Bull vs. Bear Debate: Is BTTC (D- • RQD 38/100) a Buy at $0.35?
Welcome to the BTTC (Black Titan Corporation) Roar Pit. Current RQD Composite is 38/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Pump the brakes on BTTC — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on BTTC, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Black Titan Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
BTTC cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on BTTC, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $0.35 (52-wk range $0.32 - $10.05), any beat on forward guidance forces shorts and underweight funds to chase.